Literature DB >> 26160136

European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.

Jens Bollerslev1, Lars Rejnmark2, Claudio Marcocci2, Dolores M Shoback2, Antonio Sitges-Serra2, Wim van Biesen2, Olaf M Dekkers3.   

Abstract

Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment is activated vitamin D analogues and calcium supplementation and not replacement of the lacking hormone, as in other hormonal deficiency states. The purpose of this guideline is to provide clinicians with guidance on the treatment and monitoring of chronic HypoPT in adults who do not have end-stage renal disease. We intend to draft a practical guideline, focusing on operationalized recommendations deemed to be useful in the daily management of patients. This guideline was developed and solely sponsored by The European Society of Endocrinology, supported by CBO (Dutch Institute for Health Care Improvement) and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles as a methodological base. The clinical question on which the systematic literature search was based and for which available evidence was synthesized was: what is the best treatment for adult patients with chronic HypoPT? This systematic search found 1100 articles, which was reduced to 312 based on title and abstract. The working group assessed these for eligibility in more detail, and 32 full-text articles were assessed. For the final recommendations, other literature was also taken into account. Little evidence is available on how best to treat HypoPT. Data on quality of life and the risk of complications have just started to emerge, and clinical trials on how to optimize therapy are essentially non-existent. Most studies are of limited sample size, hampering firm conclusions. No studies are available relating target calcium levels with clinically relevant endpoints. Hence it is not possible to formulate recommendations based on strict evidence. This guideline is therefore mainly based on how patients are managed in clinical practice, as reported in small case series and based on the experiences of the authors.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2015        PMID: 26160136     DOI: 10.1530/EJE-15-0628

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  81 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

2.  Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic review.

Authors:  Torben Harsløf; Lars Rolighed; Lars Rejnmark
Journal:  Endocrine       Date:  2019-02-20       Impact factor: 3.633

3.  Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.

Authors:  Karen K Winer; Andrea Kelly; Alicia Johns; Bo Zhang; Karen Dowdy; Lauren Kim; James C Reynolds; Paul S Albert; Gordon B Cutler
Journal:  J Pediatr       Date:  2018-12       Impact factor: 4.406

Review 4.  Diagnosis and management of hypocalcemia.

Authors:  Jessica Pepe; Luciano Colangelo; Federica Biamonte; Chiara Sonato; Vittoria Carmela Danese; Veronica Cecchetti; Marco Occhiuto; Valentina Piazzolla; Viviana De Martino; Federica Ferrone; Salvatore Minisola; Cristiana Cipriani
Journal:  Endocrine       Date:  2020-05-04       Impact factor: 3.633

5.  Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.

Authors:  Gerdi Tuli; Raffaele Buganza; Daniele Tessaris; Silvia Einaudi; Patrizia Matarazzo; Luisa de Sanctis
Journal:  Endocrine       Date:  2019-11-08       Impact factor: 3.633

6.  Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism.

Authors:  Ovie Edafe; Claudia E Mech; Sabapathy P Balasubramanian
Journal:  Cochrane Database Syst Rev       Date:  2019-05-22

7.  The true cost of thyroid surgery determined by a micro-costing approach.

Authors:  Sebastiano Filetti; Paul W Ladenson; Marco Biffoni; Maria Giuseppina D'Ambrosio; Laura Giacomelli; Stefania Lopatriello
Journal:  Endocrine       Date:  2016-05-12       Impact factor: 3.633

Review 8.  Risk of vertebral fractures in hypoparathyroidism.

Authors:  Anna Maria Formenti; Francesco Tecilazich; Raffaele Giubbini; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

9.  The timing of parathyroid hormone measurement defines the cut-off values to accurately predict postoperative hypocalcemia: a prospective study.

Authors:  Eduardo Bardou Yunes Filho; Rafael Vaz Machry; Rodrigo Mesquita; Rafael Selbach Scheffel; Ana Luiza Maia
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

Review 10.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.